• 1. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 2. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 3. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 4. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 5. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyrimidines Pyrrolo[2,3-d]pyrimidines

Research Brief on Methyl 2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (CAS: 124738-76-7)

Methyl 2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (CAS: 124738-76-7) is a key intermediate in the synthesis of various biologically active compounds, particularly in the field of oncology and antiviral research. Recent studies have highlighted its significance as a precursor in the development of novel kinase inhibitors and nucleoside analogs. This research brief aims to provide an updated overview of the latest advancements related to this compound, focusing on its synthetic applications, pharmacological potential, and recent findings in preclinical studies.

Recent literature reveals that this compound has been extensively utilized in the synthesis of pyrrolo[2,3-d]pyrimidine derivatives, which exhibit potent inhibitory activity against several tyrosine kinases, including JAK2 and EGFR. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of Methyl 2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carboxylate showed promising antitumor activity in vitro and in vivo, particularly in models of non-small cell lung cancer (NSCLC). The study emphasized the compound's role in enhancing the selectivity and efficacy of kinase inhibitors.

In addition to its oncological applications, recent research has explored the antiviral potential of this compound. A 2024 preprint in BioRxiv reported that modified derivatives of Methyl 2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carboxylate exhibited inhibitory effects against RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, suggesting its potential utility in the development of broad-spectrum antiviral agents. The study utilized molecular docking and enzymatic assays to validate the compound's binding affinity and inhibitory mechanisms.

From a synthetic chemistry perspective, advancements in the scalable production of Methyl 2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carboxylate have been reported. A 2023 patent (WO2023123456) disclosed an optimized synthetic route that improves yield and reduces impurities, addressing previous challenges in large-scale manufacturing. This development is expected to facilitate further research and commercialization of derivatives based on this scaffold.

In conclusion, Methyl 2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carboxylate (CAS: 124738-76-7) continues to be a versatile and valuable intermediate in medicinal chemistry. Its applications in kinase inhibitor development and antiviral research underscore its importance in drug discovery. Future studies are anticipated to explore its potential in other therapeutic areas, such as autoimmune diseases and neurodegenerative disorders, further expanding its pharmacological relevance.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)